Eli Lilly and Company (NYSE:LLY) announced today it received approval from the U.S. Food and Drug Administration for the use of ALIMTA (pemetrexed for injection), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with nonsquamous histology. ALIMTA is not indicated for treatment of patients with squamous cell non-small cell lung cancer. NSCLC is the most common form of lung cancer, resulting in more than 180,000 new cases in the U.S. each year.
The details can be read here.
No comments:
Post a Comment